• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The opening salvo of anti-complement therapy against COVID-19.

作者信息

Campbell Courtney M

机构信息

Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

出版信息

Lancet Rheumatol. 2020 Dec;2(12):e729-e730. doi: 10.1016/S2665-9913(20)30353-2. Epub 2020 Sep 28.

DOI:10.1016/S2665-9913(20)30353-2
PMID:33015642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7521911/
Abstract
摘要

相似文献

1
The opening salvo of anti-complement therapy against COVID-19.针对新冠病毒的抗补体疗法的首次出击。
Lancet Rheumatol. 2020 Dec;2(12):e729-e730. doi: 10.1016/S2665-9913(20)30353-2. Epub 2020 Sep 28.
2
Opening guns: strategy behind Carter salvo against the AMA.
Postgrad Med. 1978 Jun;63(6):16. doi: 10.1080/00325481.1978.11714848.
3
Opening Salvo.
ACR Open Rheumatol. 2019 Mar 15;1(1):3. doi: 10.1002/acr2.1004. eCollection 2019 Mar.
4
On Brown's opening salvo.
Health Serv J. 2007 Jun 7;117(6059):19.
5
[The Carabinieri Vice-Brigadiere Salvo D'Acquisto Gold Medal for Military Valour. Champion of justice and social solidarity].
G Ital Med Lav Ergon. 2006 Jan-Mar;28(1):50-2.
6
GM mosquitoes fire first salvo against Zika virus.转基因蚊子首次向寨卡病毒发起攻击。
Nat Biotechnol. 2016 Mar;34(3):221-2. doi: 10.1038/nbt0316-221.
7
Inhibition of Rho kinase: the next hopeful salvo in the long war against sepsis?
J Surg Res. 2013 Aug;183(2):542-3. doi: 10.1016/j.jss.2012.05.009. Epub 2012 May 24.
8
Steroids in alcoholic hepatitis: another salvo of data.
Am J Gastroenterol. 1992 Sep;87(9):1219-20.
9
Mrs. Clinton launches salvo at providers.
Mod Healthc. 1993 May 31;23(22):2.
10
Clinton fires latest salvo in medicare drug benefit war.克林顿在医疗保险药品福利之战中发起最新攻击。
BMJ. 2000 Apr 22;320(7242):1093.

引用本文的文献

1
Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.探索性质谱细胞术分析揭示了癌症治疗相关肺炎的免疫表型。
Elife. 2024 Apr 12;12:RP87288. doi: 10.7554/eLife.87288.
2
The complement system in pediatric acute kidney injury.补体系统与儿童急性肾损伤。
Pediatr Nephrol. 2023 May;38(5):1411-1425. doi: 10.1007/s00467-022-05755-3. Epub 2022 Oct 6.
3
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes.COVID-19 和 RA 共享一个 SPP1 髓系途径，该途径驱动 PD-L1+中性粒细胞和 CD14+单核细胞。
JCI Insight. 2021 Jun 18;6(13):e147413. doi: 10.1172/jci.insight.147413.
4
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.人类对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的先天性和适应性免疫反应：与获得性免疫和疫苗反应的相关性
Clin Exp Immunol. 2021 Jun;204(3):310-320. doi: 10.1111/cei.13582. Epub 2021 Mar 4.
5
C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.C1酯酶抑制：针对新冠病毒中的多个系统
J Clin Immunol. 2021 May;41(4):729-732. doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.

本文引用的文献

1
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.抗C5a抗体IFX-1（vilobelimab）治疗与最佳支持治疗对重症COVID-19患者的疗效比较（PANAMO）：一项探索性、开放标签的2期随机对照试验。
Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.
2
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.
3
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.在三例重症新型冠状病毒肺炎患者中使用依库珠单抗进行抗补体C5治疗。
Clin Immunol. 2020 Oct;219:108555. doi: 10.1016/j.clim.2020.108555. Epub 2020 Aug 6.
4
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.COVID-19 炎症与 C5a-C5aR1 轴的激活有关。
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
5
Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.COVID-19 患者血清的蛋白质组学和代谢组学特征。
Cell. 2020 Jul 9;182(1):59-72.e15. doi: 10.1016/j.cell.2020.05.032. Epub 2020 May 28.
6
Complement activation in patients with COVID-19: A novel therapeutic target.新型冠状病毒肺炎患者的补体激活：一个新的治疗靶点。
J Allergy Clin Immunol. 2020 Jul;146(1):215-217. doi: 10.1016/j.jaci.2020.05.006. Epub 2020 May 14.
7
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.首例 COVID-19 患者接受补体 C3 抑制剂 AMY-101 治疗。
Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29.
8
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.COVID-19 患者的依库珠单抗治疗：来自 ASL Napoli 2 Nord 真实经验的初步结果。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047. doi: 10.26355/eurrev_202004_20875.
9
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.严重 COVID-19 感染发病机制中的补体相关微血管损伤和血栓形成：五例报告。
Transl Res. 2020 Jun;220:1-13. doi: 10.1016/j.trsl.2020.04.007. Epub 2020 Apr 15.
10
Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?补体抑制会成为治疗新冠病毒相关全身性血栓形成的新靶点吗？
Circulation. 2020 Jun 2;141(22):1739-1741. doi: 10.1161/CIRCULATIONAHA.120.047419. Epub 2020 Apr 9.